Cellino

AI biomanufacturing, optical bioprocessing, regenerative medicine

replacementreplacingcell therapy

cellinobio.com·United States·$16M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-XBO5

Summary · Eternal Search editorial

Cellino AI biomanufacturing, optical bioprocessing, regenerative medicine

Cellino is developing a proprietary technology stack for personalized regenerative medicine. Its AI-driven optical bioprocesses and Nebula platform are described as enabling scalable production of patient-specific, biologically younger living medicines. The site highlights potential applications across degenerative diseases including Alzheimer’s, diabetes, Parkinson’s, kidney disease, spinal cord injury, and others.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite25

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Cellino — Far from goals · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webcellinobio.com

HQUnited States

Publications

9 on file

012026Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round.Stem cell reports→022025Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations.NPJ precision oncology→032025The BCR-SEQC initiative.Nature immunology→042024Towards accurate indel calling for oncopanel sequencing through an international pipeline competition at precisionFDA.Scientific reports→052024Extend the benchmarking indel set by manual review using the individual cell line sequencing data from the Sequencing Quality Control 2 (SEQC2) project.Scientific reports→062024Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee.Cytotherapy→072024Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing.Scientific data→082024Text summarization with ChatGPT for drug labeling documents.Drug discovery today→092021Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges.Current protocols→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Cellino

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.